Tradestie Institutional Equity Comparison Engine · Market Close Sep 17, 2026

MNMD vs SNYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MNMD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 8–2 Matrix Metrics)

MNMD Overall Winner 6-Pillar Tally: MNMD 3 – 3 SNYR Matrix Metrics: MNMD 8 – 2 SNYR

As of Sep 17, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNMD vs SNYR
MNMD NASDAQ Head-to-Head Winner
Mind Medicine (MindMed) Inc. Common Shares
Medicinal Chemicals & Botanical Products
$15.02
+1.01% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.79β · 55% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 75.0 Fund 62.0 Flow 60.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $13.52 · SMA50: $12.57
SNYR NASDAQ
Synergy CHC Corp. Common Stock
Medicinal Chemicals & Botanical Products
$0.09
-67.02% 1D
Market Cap $4.1M
TTM Revenue $28M
Forward P/E 0.6x
Beta / 30D Vol -0.86β · 868% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 55.0 Fund 39.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $0.11 · SMA50: $0.14

6-Pillar Scorecard Institutional Category Breakdown (MNMD 3 – 3 SNYR)

Columns: Metric · MNMD · SNYR
1. Valuation Multiples SNYR
Forward P/E N/M 0.6x
Trailing P/E N/M 0.6x
PEG Ratio N/M N/M
EV / Revenue N/M 0.1x
2. Growth & Scale MNMD
Revenue Growth (YoY) +0.0% -32.8%
Earnings Growth (YoY) +0.0% -90.6%
TTM Revenue (USD) N/A $28M
Market Cap $1.4B $4.1M
3. Profitability & Quality MNMD
Gross Margin N/A 65.4%
Operating Margin 0.0% -10.3%
Net Profit Margin 0.0% -57.0%
Return on Equity (ROE) -85.6% -361.1%
4. Balance Sheet & Cash Flow SNYR
Cash Generation (TTM) N/A -$3.8M
Cash Flow Margin N/A -13.7%
Net Cash / Leverage $1.70 Book/Sh · -85.6% ROE -361.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MNMD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 70.7% (6th %ile) N/A (N/A)
Put/Call OI Skew 0.18x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNYR
OpEx & R&D Intensity N/A 75.7% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Distribution Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNMD (8) vs SNYR (2)
Institutional Metric MNMD SNYR Criterion Row Edge
Market Capitalization
Scale
$1.4B $4.1M Larger Scale MNMD
Trailing P/E Ratio
Valuation
N/M 0.6x Lower Multiple SNYR
Forward P/E Ratio
Valuation
N/M 0.6x Lower Multiple SNYR
Revenue Growth (YoY)
Growth
+0.0% -32.8% Higher Growth MNMD
Operating Margin (TTM)
Profitability
0.0% -10.3% Higher Margin MNMD
Net Profit Margin
Profitability
0.0% -57.0% Higher Margin MNMD
Return on Equity (ROE)
Capital Efficiency
-85.6% -361.1% Higher ROE MNMD
52-Week Range Position
Momentum
98% ($5–$15) 1% ($0–$3) Stronger Trend MNMD
Beta / 30D Volatility
Risk Regime
1.79β · 55% Vol -0.86β · 868% Vol Lower Realized Risk MNMD
Unified Institutional Score
Composite Signal
63.1 / 100 (BUY) 48.9 / 100 (HOLD) Higher Composite MNMD
Trailing 12M Revenue (USD)
Operating Scale
N/A $28M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 65.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.70 Book/Sh · -85.6% ROE) -$3.8M (-361.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNMD +22.73 pp
MNMD: +19.54% · SNYR: -3.19%
3M Horizon MNMD +41.24 pp
MNMD: +19.02% · SNYR: -22.22%
6M Horizon MNMD +77.24 pp
MNMD: +54.69% · SNYR: -22.55%
1Y Horizon MNMD +77.24 pp
MNMD: +54.69% · SNYR: -22.55%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNMD vs SNYR. Trailing 12-month operating profitability (MNMD 0.0% vs SNYR -10.3%) and valuation multiples (MNMD N/M vs SNYR 0.6x Forward P/E) are benchmarked directly in Pillar 4 below.

MNMD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.6% · N/M
SNYR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$28M
Gross Margin65.4%
Op. Margin-10.3%
ROE / Fwd P/E-361.1% · 0.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNMD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 70.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MNMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SNYR Moat Profile Cyclical / Execution-Driven Positioning
Medical Distribution Operator
Competes within the Medical Distribution value chain with $4.1M market capitalization and -10.3% operating margin.
OpEx & R&D Reinvestment 75.7% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ MNMD vs SNYR Key Questions & Quantitative Answers

As of Sep 17, 2026, Mind Medicine (MindMed) Inc. Common Shares (MNMD) is the stronger overall head-to-head candidate over Synergy CHC Corp. (SNYR) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas SNYR carries 48.9/100 (HOLD) at $0.09 (0.6x Forward P/E, -10.3% operating margin). Technically, MNMD sits in a Markup phase (RSI 65.3, UNCLASSIFIED options structure) and SNYR sits in a Neutral phase (RSI 46.3, UNCLASSIFIED options structure).

MNMD leads the Growth & Scale pillar: MNMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SNYR at -32.8% YoY revenue growth and -90.6% YoY earnings growth on $28M TTM revenue (65.4% gross margin, -10.3% operating margin). On trailing 12-month operating scale, MNMD generates N/A in USD-normalized revenue versus $28M for SNYR. In operating R&D and SG&A reinvestment, MNMD deploys N/A (0 90-day corporate R&D disclosures) versus 75.7% of Rev ($21M) (0 disclosures) for SNYR.

SNYR screens cheaper on headline valuation multiples. MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SNYR trades at 0.6x Forward P/E, 0.6x Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-13.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNMD (-85.6% ROE) versus SNYR (-361.1% ROE) capital efficiency.

In options market volatility and institutional positioning, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk). By comparison, SNYR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.86β · 868% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Sep 17, 2026. For educational research only; not investment advice.